Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 3.73
ALNY's Cash-to-Debt is ranked lower than
64% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ALNY: 3.73 )
Ranked among companies with meaningful Cash-to-Debt only.
ALNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.29  Med: No Debt Max: No Debt
Current: 3.73
Equity-to-Asset 0.73
ALNY's Equity-to-Asset is ranked higher than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALNY: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
ALNY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.64 Max: 0.92
Current: 0.73
-0.99
0.92
Interest Coverage N/A
ALNY's Interest Coverage is ranked lower than
54% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: 11.02
Beneish M-Score: -2.17
WACC vs ROIC
22.78%
-111.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -716.42
ALNY's Operating Margin % is ranked lower than
73% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ALNY: -716.42 )
Ranked among companies with meaningful Operating Margin % only.
ALNY' s Operating Margin % Range Over the Past 10 Years
Min: -900.33  Med: -188.54 Max: -28.95
Current: -716.42
-900.33
-28.95
Net Margin % -705.11
ALNY's Net Margin % is ranked lower than
74% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ALNY: -705.11 )
Ranked among companies with meaningful Net Margin % only.
ALNY' s Net Margin % Range Over the Past 10 Years
Min: -869.63  Med: -163.4 Max: -27.3
Current: -705.11
-869.63
-27.3
ROE % -41.00
ALNY's ROE % is ranked lower than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ALNY: -41.00 )
Ranked among companies with meaningful ROE % only.
ALNY' s ROE % Range Over the Past 10 Years
Min: -84.12  Med: -39.64 Max: -13.08
Current: -41
-84.12
-13.08
ROA % -32.33
ALNY's ROA % is ranked lower than
52% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ALNY: -32.33 )
Ranked among companies with meaningful ROA % only.
ALNY' s ROA % Range Over the Past 10 Years
Min: -48.05  Med: -23.41 Max: -5.01
Current: -32.33
-48.05
-5.01
ROC (Joel Greenblatt) % -512.30
ALNY's ROC (Joel Greenblatt) % is ranked lower than
53% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ALNY: -512.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2120.98  Med: -554.62 Max: -149.42
Current: -512.3
-2120.98
-149.42
3-Year Revenue Growth Rate -10.40
ALNY's 3-Year Revenue Growth Rate is ranked lower than
68% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALNY: -10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.15 Max: 108
Current: -10.4
0
108
3-Year EBITDA Growth Rate 52.70
ALNY's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ALNY: 52.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 3.5 Max: 65.3
Current: 52.7
-64.8
65.3
3-Year EPS without NRI Growth Rate 48.90
ALNY's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ALNY: 48.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.7  Med: 6.6 Max: 52.8
Current: 48.9
-66.7
52.8
GuruFocus has detected 3 Warning Signs with Alnylam Pharmaceuticals Inc $ALNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALNY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ALNY Guru Trades in Q2 2016

Dodge & Cox 2,516,669 sh (New)
John Paulson 19,300 sh (+56.91%)
John Griffin 1,320,000 sh (+22.79%)
Vanguard Health Care Fund 8,512,270 sh (unchged)
Jim Simons 18,673 sh (-91.27%)
» More
Q3 2016

ALNY Guru Trades in Q3 2016

Dodge & Cox 5,276,068 sh (+109.64%)
John Paulson 19,300 sh (unchged)
Vanguard Health Care Fund 8,512,270 sh (unchged)
John Griffin 1,320,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2016

ALNY Guru Trades in Q4 2016

Dodge & Cox 9,204,950 sh (+74.47%)
Vanguard Health Care Fund 8,549,357 sh (+0.44%)
John Paulson 19,300 sh (unchged)
John Griffin 1,320,000 sh (unchged)
» More
Q1 2017

ALNY Guru Trades in Q1 2017

Jim Simons 51,100 sh (New)
Pioneer Investments 87,256 sh (New)
John Griffin 1,590,000 sh (+20.45%)
Dodge & Cox 9,399,245 sh (+2.11%)
Vanguard Health Care Fund 8,549,357 sh (unchged)
John Paulson Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TSRO, NAS:IONS, NAS:BIVV, NAS:SGEN, NAS:EXEL, NAS:KITE, NAS:UTHR, NAS:TECH, NAS:CLVS, NAS:NBIX, NAS:BLUE, NAS:PTLA, NAS:ACAD, NAS:PBYI, NAS:NKTR, NAS:ICPT, NAS:JUNO, NAS:SAGE, NAS:RARE, NYSE:XON » details
Traded in other countries:DUL.Germany,
Headquarter Location:USA
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates--including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Upfront fees from research partnerships with firms such as Sanofi, Novartis, Medtronic, and Roche have boosted Alnylam's cash levels, and the firm stands to see milestones and royalties from drugs commercialized under these agreements.

Top Ranked Articles about Alnylam Pharmaceuticals Inc

High Return Covered Call Trades for Alnylam Pharmaceuticals, Lumber Liquidators, Nutrisystem, 500.Com, and Wix.com!
Weekly Top Insider Buys Highlight for Week of Oct. 14 Top insider buys of the week, including Monsanto, Alnylam Pharmaceuticals, Synergy Resources and Ferrellgas Partners
Largest Insider buys for Monsanto (NYSE:MON), Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Synergy Resources Corp. (SYRG) and Ferrellgas Partners LP (NYSE:FGP). Read more...
Low Valuation Ratios Lead to Strong Portfolio Returns Backtesting Ben Graham’s Lost Formula strategy
Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market. Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.42
ALNY's PB Ratio is ranked lower than
78% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ALNY: 8.42 )
Ranked among companies with meaningful PB Ratio only.
ALNY' s PB Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.86 Max: 21.37
Current: 8.42
2.07
21.37
PS Ratio 119.24
ALNY's PS Ratio is ranked lower than
87% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ALNY: 119.24 )
Ranked among companies with meaningful PS Ratio only.
ALNY' s PS Ratio Range Over the Past 10 Years
Min: 3.1  Med: 21.14 Max: 222.78
Current: 119.24
3.1
222.78
EV-to-EBIT -15.74
ALNY's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ALNY: -15.74 )
Ranked among companies with meaningful EV-to-EBIT only.
ALNY' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.7  Med: -10.8 Max: -1.3
Current: -15.74
-61.7
-1.3
EV-to-EBITDA -16.26
ALNY's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ALNY: -16.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -95.7  Med: -11.8 Max: -1.4
Current: -16.26
-95.7
-1.4
Current Ratio 6.23
ALNY's Current Ratio is ranked higher than
65% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ALNY: 6.23 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.97 Max: 18.24
Current: 6.23
1.88
18.24
Quick Ratio 6.23
ALNY's Quick Ratio is ranked higher than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ALNY: 6.23 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.97 Max: 18.24
Current: 6.23
1.88
18.24
Days Sales Outstanding 120.83
ALNY's Days Sales Outstanding is ranked lower than
78% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ALNY: 120.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 120.83
0.57
288.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
ALNY's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ALNY: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -15.2 Max: -1
Current: -10.5
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 27.37
ALNY's Price-to-Net-Cash is ranked lower than
83% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ALNY: 27.37 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALNY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.7  Med: 9.38 Max: 92.77
Current: 27.37
3.7
92.77
Price-to-Net-Current-Asset-Value 23.85
ALNY's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ALNY: 23.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALNY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.54  Med: 9.15 Max: 82.06
Current: 23.85
3.54
82.06
Price-to-Tangible-Book 8.44
ALNY's Price-to-Tangible-Book is ranked lower than
70% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ALNY: 8.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.2  Med: 4.9 Max: 15.16
Current: 8.44
2.2
15.16
Price-to-Median-PS-Value 5.64
ALNY's Price-to-Median-PS-Value is ranked lower than
95% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ALNY: 5.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.12 Max: 9.03
Current: 5.64
0.16
9.03
Earnings Yield (Greenblatt) % -6.36
ALNY's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ALNY: -6.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -79.8  Med: -9.2 Max: -1.6
Current: -6.36
-79.8
-1.6

More Statistics

Revenue (TTM) (Mil) $58.77
EPS (TTM) $ -4.82
Beta3.46
Short Percentage of Float22.06%
52-Week Range $31.38 - 86.92
Shares Outstanding (Mil)86.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 76 145 214
EPS ($) -5.43 -5.66 -4.13
EPS without NRI ($) -5.43 -5.66 -4.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:ALNY

Headlines

Articles On GuruFocus.com
7 Outperforming Stocks With Rising Prices Jun 27 2017 
High Return Covered Call Trades for Alnylam Pharmaceuticals, Lumber Liquidators, Nutrisystem, 500.Co Apr 04 2017 
Weekly Top Insider Buys Highlight for Week of Oct. 14 Oct 16 2016 
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Liberty Broadband, Hanmi Bank Among Popular Micro-Cap Stocks Apr 04 2016 
Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam Pharmaceutical Nov 17 2015 
Julian Robertson Boosts His Stakes in JD.com, Netflix Oct 06 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 

More From Other Websites
Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth Jul 12 2017
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data Jul 11 2017
Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma Jul 11 2017
Could Alnylam Have An Edge On This Smaller Biotech In Rare Disease? Jul 10 2017
Alnylam Commences Phase III Study for Hemophilia Candidate Jul 10 2017
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study... Jul 10 2017
Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study... Jul 10 2017
Alnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why Jul 07 2017
Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic... Jul 07 2017
Biotechs Gained $1.7 Billion Last Week — Can They Keep Going? Jul 05 2017
Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod Jun 29 2017
5 Biotech Stocks With Major Catalysts in July Jun 28 2017
[$$] Alnylam Selloff Looks Like an Overreaction Jun 28 2017
Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of... Jun 26 2017
Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi... Jun 26 2017
5 Best Biotech Stocks of 2017 So Far Jun 25 2017
Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term Jun 19 2017
Why is Alnylam's (ALNY) Stock Close to 100% this Year? Jun 15 2017
Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and... Jun 12 2017
Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report? Jun 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}